710 related articles for article (PubMed ID: 21220476)
1. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
[TBL] [Abstract][Full Text] [Related]
2. Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis.
Bagnato A; Rosanò L
Cells Tissues Organs; 2007; 185(1-3):85-94. PubMed ID: 17587812
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
Spinella F; Rosanò L; Di Castro V; Nicotra MR; Natali PG; Bagnato A
Clin Cancer Res; 2004 Jul; 10(14):4670-9. PubMed ID: 15269139
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Natali PG; Bagnato A
Can J Physiol Pharmacol; 2010 Jun; 88(6):676-81. PubMed ID: 20628434
[TBL] [Abstract][Full Text] [Related]
5. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells.
Rosanò L; Spinella F; Di Castro V; Nicotra MR; Dedhar S; de Herreros AG; Natali PG; Bagnato A
Cancer Res; 2005 Dec; 65(24):11649-57. PubMed ID: 16357176
[TBL] [Abstract][Full Text] [Related]
6. The endothelin A receptor and epidermal growth factor receptor signaling converge on β-catenin to promote ovarian cancer metastasis.
Cianfrocca R; Tocci P; Spinella F; Di Castro V; Bagnato A; Rosanò L
Life Sci; 2012 Oct; 91(13-14):550-6. PubMed ID: 22480520
[TBL] [Abstract][Full Text] [Related]
7. Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression.
Rosanò L; Spinella F; Di Castro V; Decandia S; Nicotra MR; Natali PG; Bagnato A
Exp Biol Med (Maywood); 2006 Jun; 231(6):1128-31. PubMed ID: 16741062
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
Rosanò L; Spinella F; Salani D; Di Castro V; Venuti A; Nicotra MR; Natali PG; Bagnato A
Cancer Res; 2003 May; 63(10):2447-53. PubMed ID: 12750265
[TBL] [Abstract][Full Text] [Related]
9. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells.
Kajiyama H; Shibata K; Terauchi M; Yamashita M; Ino K; Nawa A; Kikkawa F
Int J Oncol; 2007 Aug; 31(2):277-83. PubMed ID: 17611683
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of the endothelin a receptor in human nasopharyngeal carcinoma.
Mai HQ; Zeng ZY; Feng KT; Ye YL; Zhang CQ; Liang WJ; Guo X; Mo HY; Hong MH
Cancer Sci; 2006 Dec; 97(12):1388-95. PubMed ID: 17032313
[TBL] [Abstract][Full Text] [Related]
11. Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity.
Rosanò L; Di Castro V; Spinella F; Tortora G; Nicotra MR; Natali PG; Bagnato A
Cancer Res; 2007 Jul; 67(13):6351-9. PubMed ID: 17616694
[TBL] [Abstract][Full Text] [Related]
12. miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma.
Sestito R; Cianfrocca R; Rosanò L; Tocci P; Semprucci E; Di Castro V; Caprara V; Ferrandina G; Sacconi A; Blandino G; Bagnato A
Oncotarget; 2016 Jan; 7(4):4009-23. PubMed ID: 26675258
[TBL] [Abstract][Full Text] [Related]
13. Emerging role of the endothelin axis in ovarian tumor progression.
Bagnato A; Spinella F; Rosanò L
Endocr Relat Cancer; 2005 Dec; 12(4):761-72. PubMed ID: 16322321
[TBL] [Abstract][Full Text] [Related]
14. Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells.
Ghoul A; Serova M; Astorgues-Xerri L; Bieche I; Bousquet G; Varna M; Vidaud M; Phillips E; Weill S; Benhadji KA; Lokiec F; Cvitkovic E; Faivre S; Raymond E
Cancer Res; 2009 May; 69(10):4260-9. PubMed ID: 19417139
[TBL] [Abstract][Full Text] [Related]
15. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
[TBL] [Abstract][Full Text] [Related]
16. Acquisition of paclitaxel resistance via PI3K‑dependent epithelial‑mesenchymal transition in A2780 human ovarian cancer cells.
Du F; Wu X; Liu Y; Wang T; Qi X; Mao Y; Jiang L; Zhu Y; Chen Y; Zhu R; Han X; Jin J; Ma X; Hua D
Oncol Rep; 2013 Sep; 30(3):1113-8. PubMed ID: 23807572
[TBL] [Abstract][Full Text] [Related]
17. ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation.
Rosanò L; Di Castro V; Spinella F; Decandia S; Natali PG; Bagnato A
Exp Biol Med (Maywood); 2006 Jun; 231(6):1132-5. PubMed ID: 16741063
[TBL] [Abstract][Full Text] [Related]
18. Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells.
Chan DW; Liu VW; Tsao GS; Yao KM; Furukawa T; Chan KK; Ngan HY
Carcinogenesis; 2008 Sep; 29(9):1742-50. PubMed ID: 18632752
[TBL] [Abstract][Full Text] [Related]
19. Strong cytotoxic effect of the bradykinin antagonist BKM-570 in ovarian cancer cells--analysis of the molecular mechanisms of its antiproliferative action.
Jutras S; Bachvarova M; Keita M; Bascands JL; Mes-Masson AM; Stewart JM; Gera L; Bachvarov D
FEBS J; 2010 Dec; 277(24):5146-60. PubMed ID: 21078129
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo.
Bardella C; Dettori D; Olivero M; Coltella N; Mazzone M; Di Renzo MF
Clin Cancer Res; 2007 Apr; 13(7):2191-8. PubMed ID: 17404103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
